Patents Assigned to Sumitomo Dainippon Pharma Co., Ltd.
  • Publication number: 20190315734
    Abstract: The present invention addresses the problem of providing a purification method for a 5-(thiazol-4-yl)indolin-2-one derivative that is useful as a medication. The present invention provides a purification method for a compound represented by formula (1) (in the formula, each n is independently 2, 3, 4, 5, or 6, R1 and R2 are identical or different and each independently represent a C1-6 alkyl group, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 each represent a hydrogen atom, a C1-6 alkyl group, an aryl group, or a heteroaryl group), or a geometric isomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof. The purification method includes a purification step performed using a solid-phase support adsorbent in the presence of a purification solvent.
    Type: Application
    Filed: June 27, 2019
    Publication date: October 17, 2019
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Akihito NONOYAMA, Kazuki HASHIMOTO
  • Publication number: 20190308958
    Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.
    Type: Application
    Filed: April 24, 2019
    Publication date: October 10, 2019
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hitoshi Watanabe, Yoshiaki Isobe, Hidenori Kimura, Yuji Fujiwara
  • Publication number: 20190290579
    Abstract: The present invention provides an orally disintegrating tablet with improved photostability of a medicament unstable to light. The orally disintegrating tablet has an inner core and an outer layer that covers the surface of the inner core, wherein the inner core contains the medicament unstable to light and the outer layer contains a light-absorbing substance such as Red No. 2, Red No. 3, Yellow No. 4, Yellow No. 5, Blue No. 1, Red No. 3 aluminum lake, Yellow No. 4 aluminum lake, Yellow No. 5 aluminum lake, Blue No. 1 aluminum lake, Blue No. 2 aluminum lake, red ferric oxide, yellow ferric oxide, black iron oxide, carmine, or sodium copper chlorophyllin.
    Type: Application
    Filed: December 14, 2018
    Publication date: September 26, 2019
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Mitsuhiro MATONO, Hirohisa KOBAYASHI, Yuki IKEDA, Yasushi OCHIAI
  • Patent number: 10407395
    Abstract: The present invention provides a medicament for treating a disease involving Nav 1.7 such as neuropathic pain, nociceptive pain, inflammatory pain, small-fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria, and multiple sclerosis, which comprises a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c and R1d are hydrogen, halogen, cyano, C1-4 alkyl, C1-4 alkoxy, or the like, provided that at least one of R1a, R1b, R1c and R1d is C6-10 aryl, C6-10 aryloxy, or the like, R2 and R3 are hydrogen, C1-6 alkyl, C3-10 cycloalkyl, or the like, R4 is hydrogen, C1-6 alkyl, C3-7 cycloalkyl, or the like, m is 1, 2 or 3, L is CR7R8, and R7 and R8 are hydrogen, hydroxyl, C1-4 alkyl, C1-4 alkoxy, or the like.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: September 10, 2019
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Masafumi Komiya, Kohei Iwamoto, Toshio Kanai, Shingo Mizushima, Keiji Adachi, Kuniko Urashima
  • Publication number: 20190263769
    Abstract: The invention addresses the problem of providing a method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione that is suited to industrial production. The invention provides a method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione by reacting 3-bromo-3-buten-2-one and 2-hydroxy-1,4-naphthoquinone in the presence of a solvent, then obtaining crystals of 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione by adding an alcohol-based solvent and/or water to the reaction system, and treating the crystals by using a specific adsorbent in the presence of a solvent.
    Type: Application
    Filed: May 10, 2019
    Publication date: August 29, 2019
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Toshikazu YAGI, Satoshi SUZUKI, Hiroto TATAMIDANI, Kazuki HASHIMOTO
  • Publication number: 20190254976
    Abstract: The invention provides a particle composed of a shell and a hollow, wherein the shell contains a medicament and a polymer, and a volume ratio of the hollow relative to the whole particle is 1%-50%. The invention also provides a process for preparation of the hollow particle, which includes a step of granulating a powder mixture containing a medicament and a polymer, while spraying a solvent capable of dissolving the polymer.
    Type: Application
    Filed: May 2, 2019
    Publication date: August 22, 2019
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Mitsuaki KOBIKI, Yasushi Ochiai
  • Patent number: 10377749
    Abstract: The present invention addresses the problem of providing a purification method for a 5-(thiazol-4-yl)indolin-2-one derivative that is useful as a medication. The present invention provides a purification method for a compound represented by formula (1) (in the formula, each n is independently 2, 3, 4, 5, or 6, R1 and R2 are identical or different and each independently represent a C1-6 alkyl group, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 each represent a hydrogen atom, a C1-6 alkyl group, an aryl group, or a heteroaryl group), or a geometric isomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof. The purification method includes a purification step performed using a solid-phase support adsorbent in the presence of a purification solvent.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: August 13, 2019
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Akihito Nonoyama, Kazuki Hashimoto
  • Patent number: 10329267
    Abstract: The invention addresses the problem of providing a method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione that is suited to industrial production. The invention provides a method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione by reacting 3-bromo-3-buten-2-one and 2-hydroxy-1,4-naphthoquinone in the presence of a solvent, then obtaining crystals of 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione by adding an alcohol-based solvent and/or water to the reaction system, and treating the crystals by using a specific adsorbent in the presence of a solvent.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: June 25, 2019
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Toshikazu Yagi, Satoshi Suzuki, Hiroto Tatamidani, Kazuki Hashimoto
  • Patent number: 10323024
    Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: June 18, 2019
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hitoshi Watanabe, Yoshiaki Isobe, Hidenori Kimura, Yuji Fujiwara
  • Publication number: 20190169191
    Abstract: The present invention relates to a substituted purine derivative of formula (1) wherein R1 is alkoxy or the like, R2 is alkyl or the like, Ring Q1 is aryl or the like, W1 is alkylene or the like, Ring Q2 is aromatic carbocyclyl or the like, n is 1-4, R3 is hydrogen atom or the like, X1 is single bond or the like, W2 is alkylene or the like, and R4 is hydrogen atom or the like, or a pharmaceutically acceptable salt thereof, which has a potent inhibitory effect against TLR7, and thereby is useful for treating autoimmune disease.
    Type: Application
    Filed: April 25, 2017
    Publication date: June 6, 2019
    Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Shingo TOJO, Yoshiaki ISOBE, Eiji IDEUE, Hiroaki FUJIWARA, Daisuke URABE
  • Patent number: 10294237
    Abstract: The present invention provides a bicyclic heterocyclic amide derivative of formula (1) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)—, etc. wherein R3a is hydrogen atom or C1-6 alkyl group; Cy1 is the following group of formula (11), etc.; ring Q2 is optionally-substituted benzene ring, etc.; n and m are independently 0, 1 or 2, provided that n and m are not simultaneously 0; X is NR5, etc.; R5 is hydrogen atom, etc.; p is 1, 2, 3, 4 or 5; R4 is, independently when two or more exist, hydrogen atom, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming ability of cancer cells and are useful as an orally-available anti-tumor agent.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: May 21, 2019
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hitoshi Ban, Manabu Kusagi, Yosuke Takanashi, Futoshi Hasegawa
  • Publication number: 20190127690
    Abstract: The present invention provides a method for producing a retinal cell or a retinal tissue, including the following steps (1)-(3): (1) a first step of culturing pluripotent stem cells in the absence of feeder cells in a medium containing 1) a TGF? family signal transduction pathway inhibiting substance and/or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining undifferentiated state, (2) a second step of culturing the cells obtained in the first step in suspension in a medium containing a Wnt signal transduction pathway inhibiting substance to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a Wnt signal transduction pathway inhibiting substance in a medium containing a BMP signal transduction pathway activating substance to obtain an aggregate containing a retinal cell or a retinal tissue.
    Type: Application
    Filed: April 21, 2017
    Publication date: May 2, 2019
    Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Atsushi KUWAHARA, Suguru YAMASAKI, Yoshiki SASAI (Deceased), Masayo TAKAHASHI
  • Publication number: 20190119220
    Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.
    Type: Application
    Filed: October 23, 2018
    Publication date: April 25, 2019
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Seiji Hori, Futoshi Hasegawa, Daisuke Urabe, Hirotaka Kurebayashi
  • Publication number: 20190112575
    Abstract: A cell population comprising Corin- and/or Lrtm1-positive cells was produced by the following steps (1) and (2), from which Corin positive and/or Lrtm1 positive cells are collected using a substance that binds to Corin and/or a substance that binds to Lrtm1, and dopaminergic neuron progenitor cells are produced by performing suspension culture of the Corin positive and/or Lrtm1 positive cells in a culture solution containing one or more nutritional factors: (1) a step of performing adhesion culture of pluripotent stem cells in a medium for maintaining undifferentiated state containing a Sonic hedgehog (SHH) signal stimulant, and an undifferentiated state-maintaining factor in the absence of feeder cells but in the presence of an extracellular matrix, and (2) a step of culturing the cell population obtained in the step (1) in a culture solution containing one or more differentiation-inducing factors.
    Type: Application
    Filed: April 24, 2017
    Publication date: April 18, 2019
    Applicants: KYOTO UNIVERSITY, SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Jun TAKAHASHI, Daisuke DOI, Kenji YOSHIDA, Atsushi KUWAHARA, Masayo TAKAHASHI
  • Patent number: 10260068
    Abstract: The invention provides a prophylactic agent or therapeutic agent for fibrodysplasia ossificans progressiva, containing as an active ingredient a binding inhibitor that inhibits interaction between activin and activin A receptor type I (ACVR1), or an expression suppressor that suppresses expression of activin.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: April 16, 2019
    Assignees: Sumitomo Dainippon Pharma Co., Ltd., Kyoto University
    Inventors: Kyosuke Hino, Junya Toguchida, Makoto Ikeya
  • Publication number: 20190084955
    Abstract: The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(?O)B, —C(?O)CR3AR3BB, —CO2B, —C(?S)OB, —CONR3CB, —C(?S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.
    Type: Application
    Filed: November 19, 2018
    Publication date: March 21, 2019
    Applicants: BOSTON BIOMEDICAL, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hitoshi BAN, Seiji KAMIOKA, Yusuke SAWAYAMA, Chiang Jia LI
  • Publication number: 20190083490
    Abstract: The present invention relates to a comprising (A) an active ingredient which is hardly soluble in water, but soluble in a C1-4 lower alcohol that may contain 30 vol % or less water, (B) polyvinyl alcohol having a saponification rate of 55-99%, and (C) a non-ionic surfactant, wherein the (A) active ingredient has a mean particle size of 10-300 nm, and a process thereof.
    Type: Application
    Filed: March 9, 2017
    Publication date: March 21, 2019
    Applicant: Sumitomo Dainippon Pharma Co. Ltd.
    Inventor: Shunsuke SAITO
  • Publication number: 20190070122
    Abstract: To provide to a transdermal absorption-type patch preparation containing zonisamide, that is a transdermal absorption-type patch preparation containing zonisamide or an alkali metal salt thereof, being capable of maintaining a high concentration of a drug in a dissolved state in the preparation and exhibiting sufficient and sustained drug efficacy. A transdermal absorption-type patch preparation containing an adhesive layer, the adhesive layer containing zonisamide or an alkali metal salt thereof, an adhesive agent containing a (meth)acrylic copolymer having a pyrrolidone group, and a transdermal absorption promoter containing N-alkylpyrrolidone.
    Type: Application
    Filed: March 24, 2017
    Publication date: March 7, 2019
    Applicants: TEIKOKU SEIYAKU CO., LTD., Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Katsuyuki INOO, Daiki TAKANO
  • Publication number: 20190062294
    Abstract: Provided is a method for producing a 2-alkylcarbonylnaphtho[2,3-b]furan-4,9-dione-related substance, which is suitable for the production on an industrial scale. The present invention provides: a method for producing an intermediate for the production of a 2-alkylcarbonyl[2,3-b]furan-4,9-dione, which comprises reacting a 1-butyne derivative in which a ketone or an alcohol is protected with a 2-hydroxy-1,4-naphthoquinone derivative having a leaving group at position-3 in a solvent in the presence of a metal or a metal compound and a base; and a substance relating to the intermediate.
    Type: Application
    Filed: March 24, 2017
    Publication date: February 28, 2019
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Kazuhiko TAKAHASHI, Shoji WATANABE, Katsuya UCHIYAMA, Kento SENAMI
  • Publication number: 20190054141
    Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
    Type: Application
    Filed: August 23, 2018
    Publication date: February 21, 2019
    Applicants: Sapporo Medical University, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Satoh, Kenjiro Kamiguchi, Rena Morita, Satoshi Nishizawa, Akari Takahashi